Retatrutide and Cancer

Retatrutide (LY3437943) is an investigational drug. It is not FDA-approved for any indication and is not an approved cancer treatment or cancer-prevention agent. This page summarizes the GLP-1 class thyroid precaution, early observational research, and what remains unknown. Nothing here constitutes medical advice.

All FDA-approved GLP-1 receptor agonists carry a class warning regarding thyroid C-cell tumors (medullary thyroid carcinoma, MTC). This warning is based on rodent studies showing dose- and duration-dependent thyroid C-cell hyperplasia and tumors with GLP-1 agonist exposure. Human relevance has not been established for any GLP-1 agonist. Because retatrutide has no FDA-approved prescribing label, there is no official retatrutide-specific contraindication — however, retatrutide trial protocols exclude participants with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), consistent with the class-level precaution applied to approved drugs.

Post-marketing surveillance of approved GLP-1 agonists (liraglutide, semaglutide) has not established a causal link between GLP-1 receptor agonism and medullary thyroid carcinoma in humans. A 2023 analysis in JAMA Internal Medicine (Bezin et al.) found a small increased association between liraglutide/exenatide use and thyroid cancer in a French pharmacovigilance database, but the absolute risk was low and the study had significant methodological limitations. The FDA has not issued an updated warning based on post-marketing human data. The class precaution remains in place as a precautionary measure.

Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is a leading driver of hepatocellular carcinoma (HCC), the most common form of liver cancer. Retatrutide's glucagon receptor agonism promotes hepatic fat oxidation, and a Phase 2 substudy published in Nature Medicine (2024) showed significant reductions in liver fat content measured by MRI-PDFF. The hypothesis is that by reducing liver fat and inflammation in MASLD/MASH, retatrutide might reduce the long-term risk of MASH-related HCC. This is a plausible mechanistic hypothesis, not an established finding. No trial has studied retatrutide's effect on HCC incidence.

Several large observational studies have examined whether GLP-1 receptor agonists are associated with reduced incidence of obesity-related cancers. A 2024 study in JAMA Oncology (Yeo et al.) found that semaglutide use was associated with significantly lower incidence of 10 of 13 obesity-related cancers compared to insulin use in patients with type 2 diabetes. These are observational findings subject to confounding, selection bias, and the healthy-user effect. They do not establish causation and do not involve retatrutide specifically. No randomized trial has tested any GLP-1 agonist for cancer prevention as a primary endpoint.

No published study has examined retatrutide's effects on cancer incidence or tumor biology in humans. Retatrutide activates GLP-1 receptors — the same receptor implicated in the observational cancer-association data — but also activates GIP and glucagon receptors. The role of GIP and glucagon receptor agonism in cancer biology is less studied. Whether retatrutide's triple-receptor mechanism would produce different cancer-related outcomes compared to GLP-1-only agonists is unknown. The TRIUMPH program does not include cancer incidence as a primary or secondary endpoint.

Key open questions include: (1) Does the GLP-1 class thyroid C-cell signal in rodents translate to any meaningful risk in humans? (2) Do GLP-1 agonists reduce obesity-related cancer incidence in randomized trials? (3) Does retatrutide's liver-fat reduction translate to reduced MASH-related HCC risk over time? (4) Does triple-receptor agonism alter cancer-related biology differently than single or dual agonism? None of these questions have been answered in clinical trials.